Squamous Cell Carcinoma of the Head and Neck
Conditions
Keywords
Targeted therapies, Plasma samples
Brief summary
The investigators will collect plasma samples at baseline, during treatment, and at progression.
Detailed description
In this study, the investigators will collect plasma samples at baseline, during treatment, and at progression. This plasma bank will be used to study the potential value of some biomarkers to predict treatment activity or resistance to cetuximab or other targeted agents
Interventions
OTHERPlasma samples
Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
Sponsors
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients treated with radiation therapy and cetuximab according to Bonner et al * patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. * patients treated with a molecular targeted agent as a part of a clinical study
Exclusion criteria
* patients with another type of head and neck cancer * patients non treated with targeted therapies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prospective storage of plasma samples of patients treated with cetuximab or other targeted agents | one year after the collection | All the analyses will be done when we have enough of collected samples |
Countries
Belgium
Contacts
Primary ContactJean-Pascal Machiels, MD, PhD
Backup ContactSéverine Carlier, MD
Outcome results
None listed